PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced two EOS imaging system installations in the U.S. at the University of Florida Health Shands Hospital in Gainesville, Fla. and at Riley Hospital for Children at Indiana University in Indianapolis.
The UF Health Shands Children's Hospital is part of University of Florida Health, one of the Southeast’s most comprehensive academic health systems and is ranked in the top-50 pediatric hospitals in the country in a variety of specialties by US News & World Report.
Riley Hospital for Children at Indiana University Health was one of the first hospitals in the country to offer Patient- and Family-Centered Care. As Indiana’s only comprehensive children’s hospital, Riley provides inpatient and outpatient care to more than 300,000 children each year and is ranked 19th in the nation by US News & World Report for pediatric orthopedics.
Marie Meynadier, CEO of EOS imaging, said, “These key EOS installations illustrate the ongoing recognition of our imaging system as the gold standard in pediatric imaging. Our first installation in the state of Indiana as well as within one of the most comprehensive academic medical healthcare systems in the southeastern U.S. illustrate the sustained demand for ultra-low dose 2D/3D imaging in the U.S.”
The EOS® system provides full-body images of patients in a natural functional position in both 2D and 3D with 50% to 85% less dose than digital radiology and 95% less dose than basic CT scans, in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction, as well as associated software solutions.
For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
About EOS imaging:
EOS imaging designs, develops, and markets EOS® and associated solutions, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market in 34 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI